Patents by Inventor Dominik Filipp

Dominik Filipp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7592310
    Abstract: A method of ameliorating the symptoms of sepsis comprising directly exposing epithelial cells of a mammal in need thereof to soluble CD14, or active variants thereof. A method of obtaining CD14 from a stock solution containing protein of a mammary secretion is described. A method of directly activating B cells using a soluble polypeptide having the amino acid sequence selected from the group consisting of leu-leu-leu-leu-leu-leu-pro-ser, leu-leu-leu-leu-leu-leu-pro-leu; and leu-leu-leu-leu-leu-leu-val-his, and which is specifically recognized by the monoclonal antibody 3C10 and which activates B cells is described. Bovine CD14 genomic DNA is described.
    Type: Grant
    Filed: July 15, 2004
    Date of Patent: September 22, 2009
    Assignee: Gemma Biotechnology Ltd.
    Inventors: Michael H. Julius, Dominik Filipp
  • Publication number: 20070014809
    Abstract: A novel protein purified from bovine colostral whey and isolated nucleotide sequences encoding the protein is identified. The isolated bovine protein is termed Bovine Lactation Associated Immunotropic (Bo-LAIT) protein. The human homologue of Bo-LAIT protein, Hu-LAIT protein, is also described. A method of activating B cells, and particularly of activating B cells in a mammal, such as a human, in need of such activation by administering LAIT protein is described. LAIT protein can be incorporated into infant formula. LAIT protein can be administered to an infant, as by feeding to the infant such formula. LAIT protein can be incorporated as part of a vaccination. LAIT protein can be administered to a patient having a T cell immune deficiency, for example, a particular T cell dysfunction in which gp39 (CD40L) is under expressed on or totally absent from the cell surface of patient T cells.
    Type: Application
    Filed: June 30, 2006
    Publication date: January 18, 2007
    Applicant: The Arthritis & Autoimmunity Research Centre Foundation
    Inventors: Michael JULIUS, Dominik FILIPP, Kamel ALIZADEH-KHIAVI
  • Publication number: 20040258704
    Abstract: A novel protein purified from bovine colostral whey and isolated nucleotide sequences encoding the protein is identified. The isolated bovine protein is termed Bovine Lactation Associated Immunotropic (Bo-LAIT) protein. The human homologue of Bo-LAIT protein, Hu-LAIT protein, is also described. A method of activating B cells, and particularly of activating B cells in a mammal, such as a human, in need of such activation by administering LAIT protein is described. LAIT protein can be incorporated into infant formula. LAIT protein can be administered to an infant, as by feeding to the infant such formula. LAIT protein can be incorporated as part of a vaccination. LAIT protein can be administered to a patient having a T cell immune deficiency, for example, a particular T cell dysfunction in which gp39 (CD40L) is under expressed on or totally absent from the cell surface of patient T cells.
    Type: Application
    Filed: December 15, 2003
    Publication date: December 23, 2004
    Inventors: Michael H. Julius, Dominik Filipp, Kamel Alizadeh-Khiavi
  • Publication number: 20040259795
    Abstract: A method of ameliorating the symptoms of sepsis comprising directly exposing epithelial cells of a mammal in need thereof to soluble CD14, or active variants thereof. A method of obtaining CD14 from a stock solution containing protein of a mammary secretion is described. A method of directly activating B cells using a soluble polypeptide having the amino acid sequence selected from the group consisting of leu-leu-leu-leu-leu-leu-pro-ser, leu-leu-leu-leu-leu-leu-pro-leu; and leu-leu-leu-leu-leu-leu-val-his, and which is specifically recognized by the monoclonal antibody 3C10 and which activates B cells is described. Bovine CD14 genomic DNA is described.
    Type: Application
    Filed: July 15, 2004
    Publication date: December 23, 2004
    Applicant: GEMMA BIOTECHNOLOGY LTD.
    Inventors: Michael H. Julius, Dominik Filipp
  • Patent number: 6676985
    Abstract: A protein purified from bovine colostral whey and isolated nucleotide sequences encoding the protein is identified. The isolated bovine protein is termed Bovine Lactation Associated Immunotropic (Bo-LAIT) protein. The human homologue of Bo-LAIT protein, Hu-LAIT protein, is also described. A method of activating B cells, and particularly of activating B cells in a mammal, such as a human, in need of such activation by administering LAIT protein is described. LAIT protein can be incorporated into infant formula. LAIT protein can be administered to an infant, as by feeding to the infant such formula. LAIT protein can be incorporated as part of a vaccination, LAIT protein can be administered to a patient having a T cell immune deficiency, for example, a particular T cell dysfunction in which gp39 (CD40L) is under expressed on or totally absent from the cell surface of patient T cells. Preparation of medicaments including LAIT protein for activating B cells in a mammal in need of such activation is described.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: January 13, 2004
    Assignee: The Arthritis & Autoimmunity Research Centre Foundation
    Inventors: Michael H. Julius, Dominik Filipp, Kamel Alizadeh-Khiavi
  • Patent number: 6093693
    Abstract: A novel protein purified from bovine colostral whey and isolated nucleotide sequences encoding the protein. The isolated bovine protein has homology with human CD14 and murine CD14 and so is referred to as bovine CD14. A method of activating B cells, and particularly of activating B cells in a mammal, such as a human, in need of such activation by administering CD14 is described. CD14 can be incorporated into infant formula. CD14 can be administered to an infant, as by feeding to the infant such formula. CD14 can be incorporated as part of a vaccination. CD14 can be administered to a patient having a T cell immune deficiency, for example, a particular T cell dysfunction in which gp39 is under expressed on or totally absent from the cell surface of patient T cells. Preparation of medicaments including CD14 for activating B cells in a mammal in need of such activation is described. Natural or recombinant CD14 can be used.
    Type: Grant
    Filed: November 18, 1996
    Date of Patent: July 25, 2000
    Assignee: The Wellesley Hospital Foundation
    Inventors: Michael H. Julius, Dominik Filipp, Kamel Alizadeh-Khiavi